Michael A. Matthay MDProfessor, Medicine and Anesthesia; Associate Director, Critical Care Medicine; Senior Associate, Cardiovascular Research Institute, Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, California
Dr. Matthay's overall focus is on improving clinical care of patients with acute respiratory failure from the acute respiratory distress syndrome and from sepsis. His research work has focused on basic, clinical, and translational studies to determine the pathogenesis of acute lung injury, with a major focus on understanding the human biology and clinical determinants that account for the development and resolution of ARDS, pneumonia and sepsis.
Dr. Matthay’s laboratory developed the ex vivo perfused human lung preparation to facilitate mechanistic studies of the pathogenesis of acute lung injury and to test potential new therapies, including studies of human bone marrow derived mesenchymal stromal cells (MSCs). He has is the principal investigator on several trials testing novel therapies for ARDS including MSCs. Dr. Matthay spends a considerable time mentoring physicians and faculty in career development and academic medicine.
Dr. Matthay’s work is supported by funding from NIH grants (NHLBI and NIAID), the Department of Defense, California Institute for Regenerative Medicine, as well as industry supported grants from Genentech Roche and Quantum Health.
Dr. Matthay has consulting work with Novartis, Johnson and Johnson, Merck, Gilead, Citius Pharmaceuticals, and Pliant Therapeutics.